Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
MWN-AI** Summary
Microbot Medical Inc. (Nasdaq: MBOT), a leader in the development of innovative medical devices, has confirmed its stability and operational continuity amid recent geopolitical tensions affecting the Middle East. The company's U.S. and Israeli operations remain uninterrupted, prioritizing employee safety and security while ensuring that internal functions and manufacturing processes are fully operational. Following the recent FDA clearance of its LIBERTY® Endovascular Robotic System, Microbot is focusing on the U.S. market, leveraging a dedicated commercial team in Hingham, Massachusetts, for seamless service and distribution.
To meet anticipated demand, Microbot maintains a robust inventory and is enhancing capacity through third-party logistics partnerships. In preparation for the LIBERTY system's full market release, scheduled for the Society of Interventional Radiology (SIR) annual meeting in April 2026, the company is expanding its commercial infrastructure. This includes the hiring of new sales representatives and a Director of Health Economics and Outcomes Research to drive further market penetration.
The LIBERTY system is notable as the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, aimed at improving precision while minimizing radiation exposure and physical strain on medical personnel. Anticipation is growing in the market, and the full release at the SIR conference is poised to enhance adoption.
Microbot Medical is committed to operational excellence and closely monitors ongoing geopolitical developments to ensure sustained customer support and employee well-being. Backed by a strong intellectual property portfolio, the company is positioned at the forefront of transforming endovascular care through advanced robotics.
MWN-AI** Analysis
Microbot Medical Inc. (Nasdaq: MBOT) is navigating a complex landscape with resilience, particularly amidst current geopolitical tensions. The company's latest announcement reassures investors by confirming that operational stability continues in both the U.S. and Israel. As investors, it's crucial to understand the implications of this stability and the prospects ahead.
The LIBERTY® Endovascular Robotic System stands out in the medical technology landscape as the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. With strong initial market interest following its limited release in late 2025 and a full release anticipated at the Society of Interventional Radiology conference in April 2026, there is considerable potential for growth. Microbot’s proactive inventory management and expansion of its sales team reflect a strategic commitment to capturing market share, especially in the U.S., which is the primary focus.
Given the heightened awareness and demand for innovative healthcare solutions, the timing for Microbot could not be better. It is positioned to leverage the current healthcare market’s interest in reducing operational complexities and improving patient outcomes through its advanced technology. Additionally, the hiring of a Director of Health Economics and Outcomes Research signifies a focus on not just selling the product, but also demonstrating its value in clinical settings—an essential element for widespread adoption.
While the geopolitical risks remain, Microbot's operational continuity and strong leadership indicate a robust resourcefulness that can weather external disruptions. For investors, this operational confidence combined with a favorable product cycle presents a compelling case to consider Microbot Medical as a potential growth opportunity. Staying informed on market developments, regulatory updates, and adoption rates will be crucial for evaluating the potential for enhanced shareholder value.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner remain fully functional.
Following the recent FDA clearance of LIBERTY, the commercial focus of the Company has been on the U.S. market, managed by its dedicated U.S.-based commercial team headquartered in Hingham, MA. This ensures uninterrupted service, reliable distribution, and continued advancement of the limited market release of the LIBERTY System as planned. The Company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through its U.S.-based third-party logistics partner to meet anticipated demand.
In preparation for the full market release of the LIBERTY System at the Society of Interventional Radiology (SIR) annual meeting next month, and amid the growing market interest, the Company continues to strengthen its commercial infrastructure. It recently hired additional sales representatives to expand coverage into new U.S. territories, along with a Director of Health Economics and Outcomes Research (HEOR) to further support and enhance its commercial expansion.
The Company is closely monitoring the situation in the Middle East to ensure the ongoing well-being of its employees and to ensure uninterrupted support for customers, reinforcing its commitment to operational excellence.
LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
FAQ**
How does Microbot Medical Inc. (MBOT) plan to leverage its FDA clearance of the LIBERTY System to gain market share in the U.S. endovascular sector amid increasing competition?
With ongoing geopolitical tensions, how is Microbot Medical Inc. (MBOT) ensuring the safety of its personnel while maintaining operational efficiency?
What strategies is Microbot Medical Inc. (MBOT) employing to effectively manage inventory and distribution as demand for the LIBERTY System surges prior to its full market release?
Can Microbot Medical Inc. (MBOT) provide insights into how the newly hired Director of Health Economics and Outcomes Research will enhance commercial expansion efforts for the LIBERTY System?
**MWN-AI FAQ is based on asking OpenAI questions about Microbot Medical Inc. (NASDAQ: MBOT).
NASDAQ: MBOT
MBOT Trading
1.68% G/L:
$2.415 Last:
757,356 Volume:
$2.37 Open:
